Andreas Argyrides
Stock Analyst at Oppenheimer
(4.41)
# 349
Out of 5,113 analysts
119
Total ratings
53.4%
Success rate
20.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | $42 | $20.49 | +104.98% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $17.70 | +125.99% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.61 | +60.43% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $17.83 | +51.43% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $67.44 | +70.53% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.68 | +470.65% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $12.08 | +140.07% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.58 | +5,594.56% | 2 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $467.30 | +23.05% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.64 | +165.96% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $4.83 | +314.08% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $36.84 | +65.58% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $3.24 | +116.05% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $0.91 | +229.34% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $41.91 | -68.98% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.34 | +198.51% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $11.69 | +669.89% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.62 | +455.56% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $222.45 | -18.63% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $16.25 | +540.00% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $2.55 | +252.94% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $10.06 | +88.87% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $28.38 | +2.18% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $11.01 | +90.74% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $21.31 | +951.15% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $20.38 | +179.69% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.61 | +1,048.67% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.36 | +2,648.01% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $56.68 | +23.50% | 6 | Aug 1, 2023 |
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $20.49
Upside: +104.98%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $17.70
Upside: +125.99%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.61
Upside: +60.43%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $17.83
Upside: +51.43%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $67.44
Upside: +70.53%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.68
Upside: +470.65%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $12.08
Upside: +140.07%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.58
Upside: +5,594.56%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $467.30
Upside: +23.05%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.64
Upside: +165.96%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $4.83
Upside: +314.08%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $36.84
Upside: +65.58%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $3.24
Upside: +116.05%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.91
Upside: +229.34%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $41.91
Upside: -68.98%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.34
Upside: +198.51%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $11.69
Upside: +669.89%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.62
Upside: +455.56%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $222.45
Upside: -18.63%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $16.25
Upside: +540.00%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $2.55
Upside: +252.94%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $10.06
Upside: +88.87%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $28.38
Upside: +2.18%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $11.01
Upside: +90.74%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $21.31
Upside: +951.15%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $20.38
Upside: +179.69%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.61
Upside: +1,048.67%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.36
Upside: +2,648.01%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $56.68
Upside: +23.50%